ASH 2024 | The survival of patients with secondary malignancies and MCL

So this is a study of secondary primary malignancies in mantle cell lymphoma patients. So first we looked into the risk and 16% of our patients develop a new cancer after their mantle cell lymphoma and that’s a wide range of different types of secondary malignancies. We really saw a lot of skin cancer, but of course also more severe ones such as lung cancer, head and neck tumours, gastrointestinal tumours and secondary AML and MDS. So we looked into survival and 35% of patients with the two malignancies were alive after five years. And when we compare that to patients with similar malignancies but without prior mantle cell lymphoma, the number was as high as 80%. So the patients with the two malignancies, of course, had an over-risk of dying. And when we looked into the three-year survival, patients with a secondary AML and MDS, only 10% were alive. Then we looked into skin cancer, 40% were alive. And of course, they didn’t die from the skin cancer, but that was a surrogate for dying more of mantle cell lymphoma. And then for solid cancer, it was around 60% three years survival for our patients and for the ones with only primary malignancies and without mantle cell lymphoma, it was 80%. So I think that this calls for the awareness of a secondary malignancy and also that we should know that patients that have the two types of cancer, they need both treatment for their underlying mantle cell lymphoma and for their secondary malignancy. And that is of course a challenge, but I think we have to try to treat both types of cancer and find new concepts and ways where we can treat the mantle cell lymphoma despite that they have another malignancy.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.